关注
Daniel Grima
Daniel Grima
Cornerstone Research Group Inc.
在 cornerstone-research.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
SJ Goldie, M Kohli, D Grima, MC Weinstein, TC Wright, FX Bosch, ...
Journal of the National Cancer Institute 96 (8), 604-615, 2004
7532004
A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine
SJ Goldie, D Grima, M Kohli, TC Wright, M Weinstein, E Franco
International Journal of cancer 106 (6), 896-904, 2003
2592003
A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL
S Brown, B Hutton, T Clifford, D Coyle, D Grima, G Wells, C Cameron
Systematic reviews 3, 1-11, 2014
2282014
Cost and health related quality of life consequences of multiple sclerosis
DT Grima, GW Torrance, G Francis, G Rice, AJ Rosner, L Lafortune
Multiple Sclerosis Journal 6 (2), 91-98, 2000
2082000
Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States
DA Marshall, SH Kleinman, JB Wong, JP AuBuchon, DT Grima, NA Kulin, ...
Vox sanguinis 86 (1), 28-40, 2004
1812004
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis
CA Hutchison, N Heyne, P Airia, R Schindler, D Zickler, M Cook, ...
Nephrology Dialysis Transplantation 27 (10), 3823-3828, 2012
1742012
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions
ANA Tosteson, B Jönsson, DT Grima, BJ O’Brien, DM Black, JD Adachi
Osteoporosis international 12, 849-857, 2001
1122001
Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada
DT Grima, MF Thompson, L Sauriol
Pharmacoeconomics 25, 253-266, 2007
662007
Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs
DT Grima, LM Bernard, ES Dunn, PA McFarlane, DC Mendelssohn
Pharmacoeconomics 30, 981-989, 2012
512012
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone
AD Sung, DT Grima, LM Bernard, S Brown, G Carrum, L Holmberg, ...
Bone marrow transplantation 48 (11), 1444-1449, 2013
492013
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis
AJ Rosner, DT Grima, GW Torrance, C Bradley, JD Adachi, RJ Sebaldt, ...
Pharmacoeconomics 14, 559-573, 1998
451998
Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a …
DT Grima, A Papaioannou, P Airia, G Ioannidis, JD Adachi
BMC Musculoskeletal Disorders 11 (1), 68, 2010
422010
Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France
LM Bernard, R Althin, R Dhawan, DT Grima, A Lam, S Aballea
European journal of ophthalmology 13 (4_suppl), 30-43, 2003
372003
Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney
DT Grima, P Airia, C Attard, CA Hutchison
Current medical research and opinion 27 (2), 383-391, 2011
362011
Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium …
M Miller, L Bernard, M Thompson, D Grima, J Pepin
Infection Control & Hospital Epidemiology 31 (7), 710-715, 2010
342010
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective
JA Tanner, PE Davies, CC Overall, D Grima, J Nam, BM Dechairo
Pharmacogenomics 21 (8), 521-531, 2020
292020
Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada
CL Attard, JA Maroun, K Alloul, DT Grima, LM Bernard
Current Oncology 17 (1), 17-24, 2010
282010
Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
DT Grima, ST Brown, L Kamboj, KR Bainey, R Goeree, P Oh, ...
ClinicoEconomics and Outcomes Research, 49-62, 2014
272014
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
DT Grima, A Papaioannou, MF Thompson, MK Pasquale, JD Adachi
Osteoporosis international 19, 687-697, 2008
272008
Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture
DT Grima, RT Burge, DL Becker, ANA Tosteson
P AND T 27 (9), 448-455, 2002
272002
系统目前无法执行此操作,请稍后再试。
文章 1–20